Lv13
46 积分 2024-11-13 加入
Meta‐analysis evaluating the efficacy and safety of various Bruton tyrosine kinase (BTK) inhibitors for central nervous system lymphoma: Novel covalent BTK inhibitors, except for ibrutinib, also demonstrate good efficacy in the treatment of primary central nervous system lymphoma
15小时前
已完结
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
1天前
求助中
In vivo CAR T cell generation to treat cancer and autoimmune disease
23天前
已完结
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
23天前
已完结
Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Marginal Zone Lymphoma: Results from Phase 1/2 BRUIN Study
2个月前
已完结
The Treatment of Marginal Zone Lymphoma
2个月前
已完结
Marginal-Zone Lymphomas
2个月前
已完结
Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2个月前
已完结
Anti-GPRC5D CAR T-cell therapy as a salvage treatment in patients with progressive multiple myeloma after anti-BCMA CAR T-cell therapy: a single-centre, single-arm, phase 2 trial
4个月前
已完结
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
5个月前
已完结
皖公网安备34019202002308
